Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $6.8 million for Q3 2025.

• On a quarterly basis, Other Non-Current Liabilities rose 9.58% year-over-year to $6.8 million in Q3 2025; TTM through Sep 2025 was $6.8 million, a 9.58% increase from a year earlier, with the FY2024 full-year figure at $6.4 million, up 10.39% from the prior year.
• Other Non-Current Liabilities grew to $6.8 million in Q3 2025 per AVIR's latest filing, from $6.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $6.8 million in Q3 2025 and bottomed at $29000.0 in Q2 2021.
• The 5-year median for Other Non-Current Liabilities is $5.9 million (2021), against an average of $5.3 million.
• Biggest YoY gain for Other Non-Current Liabilities was 20617.24% in 2022; the steepest drop was 11.41% in 2022.
• Year by year, Other Non-Current Liabilities stood at $5.9 million in 2021, then decreased by 11.41% to $5.3 million in 2022, then grew by 9.57% to $5.8 million in 2023, then gained by 10.39% to $6.4 million in 2024, then grew by 6.91% to $6.8 million in 2025.
• Per Business Quant, the three latest AVIR Other Non-Current Liabilities figures stand at $6.8 million (Q3 2025), $6.6 million (Q2 2025), and $6.5 million (Q1 2025).